RxDoctor Payments Data

Claudine Kimura, MD

Pediatrics · Honolulu, HINPI 1972616670

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 27.2% of the total.

$950in general payments, 2019–2025

Across 50 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$258
  • GSK$254
  • Lilly USA, LLC$151
  • Cook Biotech Incorporated$126
  • Novo Nordisk$72
  • Amarin Pharma, Inc.$31
  • plus $58 from 2 others

What the payments were for

  • Food & beverage$950100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$950 in reported general payments places this provider in the 85th percentile of 208 pediatrics providers in Hawaii.

See all pediatrics providers in Hawaii

Medicare billing

Part B allowed, 2024
$67,255
Medicare patients
113
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin89$119,277
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$88,341
RybelsusSemaglutide21$56,032
ProliaDenosumab12$21,204
JanuviaSitagliptin Phosphate20$19,735
OzempicSemaglutide11$15,935
Raloxifene Hcl72$10,803
VascepaIcosapent Ethyl21$9,924
Rosuvastatin Calcium220$8,822
Olmesartan Medoxomil107$8,815
Atorvastatin Calcium208$5,142
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$4,005
Omega-3 Acid Ethyl Esters31$2,949
Risedronate Sodium41$2,307
Wixela InhubFluticasone Propion/Salmeterol15$1,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$30$119,27789 claims
GSKTrelegy Ellipta$254$88,34190 claims
Novo NordiskRybelsus, Ozempic$72$71,96732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 208 pediatrics providers in Hawaii.

Other pediatrics in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →